Deutsche Bank raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $18 from $16 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
- Avadel Pharmaceuticals Reports Strong Q2 Growth
- Avadel Pharmaceuticals reports Q2 EPS 10c, consensus 3c
- Avadel Pharmaceuticals sees FY25 revenue $265M-$275M, consensus $260.01M
- Avadel Pharmaceuticals sees Q3 revenue $71M-$75M, consensus $70.61M